FindTrial
Sign In

Cream vehicle

DRUG8 trials

Sponsors

Leo Pharma A/S, LEO Pharma, MC2 Therapeutics

Conditions

Atopic DermatitisChronic Hand EczemaLichen SclerosusMild to severe palmoplantar pustulosisPsoriasis Vulgaris

Phase 1

Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream
CompletedNCT01850849
LEO PharmaAtopic Dermatitis
Start: 2013-05-31End: 2014-12-31Updated: 2025-02-24

Phase 2

Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris
CompletedNCT00764751
LEO PharmaPsoriasis Vulgaris
Start: 2008-09-30End: 2009-01-31Updated: 2025-03-07
A proof-of-concept phase 2a, double-blind, 2-arm trial to investigate efficacy and safety of twice daily delgocitinib cream 20 mg/g compared with cream vehicle during a 16-week treatment period in adult subjects with mild to severe palmoplantar pustulosis
RecruitingCTIS2024-518856-21-00
Leo Pharma A/SMild to severe palmoplantar pustulosis
Start: 2025-08-28Target: 70Updated: 2025-12-03

Phase 3

A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream
CompletedNCT03308799
MC2 TherapeuticsPsoriasis Vulgaris
Start: 2017-10-03End: 2018-06-08Updated: 2024-12-09
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)
CompletedNCT04872101
LEO PharmaChronic Hand Eczema
Start: 2021-05-25End: 2023-01-06Updated: 2025-04-08
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema
CompletedNCT04871711
LEO PharmaChronic Hand Eczema
Start: 2021-05-10End: 2022-10-31Updated: 2025-04-08
Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema
CompletedNCT05355818
LEO PharmaChronic Hand Eczema
Start: 2022-07-14End: 2024-12-17Updated: 2025-07-29
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
Not yet recruitingNCT07335588
LEO PharmaLichen Sclerosus
Start: 2026-05-06End: 2028-12-29Target: 652Updated: 2026-02-20

Related Papers

Editorial: Exploring innovative therapies for rare inflammatory skin diseases
Frontiers in Medicine2026-03-19
Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema.
2026-03-03
Delgocitinib Cream Reduces Itch and Pain in Moderate to Severe Chronic Hand Eczema: Phase 3 DELTA 1 and 2 Pooled Analyses.
2025-12-24
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema.
2025-11-15
Best Responders and Super-Responders to Calcipotriol and Betamethasone Dipropionate PAD-Cream: A Post Hoc Pooled Analysis of Two Phase 3 Trials.
2025-04-24
Health-Related Quality of Life in Chronic Hand Eczema in a Phase 2b Trial of Delgocitinib Cream
Dermatology and Therapy2025-04-05
Development and Validation of a Patient-Reported Outcome Measure of the Impact of Chronic Hand Eczema on Health-Related Quality of Life: the Hand Eczema Impact Scale (HEIS)
Dermatology and Therapy2024-10-215 citations
653 - Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: pooled results of the phase 3 DELTA-1 and -2 trials
British Journal of Dermatology2024-08-016 citations
655 - Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA-3 trial
British Journal of Dermatology2024-08-015 citations
654 - Delgocitinib cream reduces itch and pain in adults with moderate to severe chronic hand eczema: pooled analyses of the phase 3 DELTA-1 and -2 trials
British Journal of Dermatology2024-08-013 citations
656 - Systemic exposure and safety profile of delgocitinib cream in adults with moderate to severe chronic hand eczema in the phase 3 DELTA-2 trial
British Journal of Dermatology2024-08-011 citations
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
2024-07-1841 citations
Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA–CHE): a new clinician reported outcome measure of CHE severity
Archives of Dermatological Research2024-03-2016 citations
Development and Psychometric Validation of a Patient-Reported Outcome Measure to Assess the Signs and Symptoms of Chronic Hand Eczema: The Hand Eczema Symptom Diary (HESD).
2024-03-157 citations
Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase 3 Studies
Dermatology and Therapy2023-07-253 citations
Efficacy, Convenience, and Safety of Calcipotriene-Betamethasone Dipropionate Cream in Skin of Color Patients With Plaque Psoriasis
Journal of Drugs in Dermatology2023-06-014 citations
A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30<sup>th</sup> EADV Congress 2021.
2023-01-014 citations
Pooled Analysis Demonstrating Superior Patient- Reported Psoriasis Treatment Outcomes for Calcipotriene/ Betamethasone Dipropionate Cream Versus Suspension/Gel.
PubMed2022-03-017 citations
Validation of the Self-Reported Psoriasis Treatment Convenience Scale (PTCS).
2021-10-146 citations
A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream.
PubMed2021-04-0111 citations

1 more papers not shown